Takeuchi Satoshi, Takada Anna, Sugiyama Toru
Dept. of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan.
Gan To Kagaku Ryoho. 2012 Oct;39(10):1471-6.
Recently, the resistant-to-paclitaxel/carboplatin therapy(TC), the standard first-line chemo-regimen for epithelial ovarian cancer(EOC), has been reported in subtypes of EOC, such as clear cell carcinoma and mucinous adenocarcinoma. The response to the chemo-regimen is evaluated by tumor markers and imaging of CT/MRI. The timing of regimen change depends on the identification of progressive disease(PD), using Rustin's criteria for CA125 and RECIST v1.1 for imaging, or severe adverse events(AEs>=grade 3, 4)in non-hematologic toxicities. For patients with refractory or recurrent EOC, the aim of their treatment was changed to keeping their quality of life for as long as possible with/without curing them from the disease. Thus, the selection of regimens for recurrent EOC should be suitable for the patient-friendly regimens, such as those with fewer AEs, out-patient- setting and shorter administration. As for molecular-targeted agents, bevacizumab and olaparib with TC therapy were reported to give patients significantly longer progression-free survival than control arms. Further investigation of immune-therapy or new agents for aiming total cell kill of tumor cell is should be warranted to obtain longer overall survival in patients with advanced EOC.
